Evaluation of Immune response to Intravenously Administered Human Cord Blood Stem Cells in the Treatment of Symptoms Related to Chronic Inflammation

Abstract

Objective: Numerous investigations suggest that Mesenchymal Stem Cells (MSCs) in general represent a valuable tool for therapy of symptoms related to chronic inflammatory diseases. Blue Horizon Stem Cell Therapy Program is a leading provider of adult and children's stem cell therapies. Uniquely we have safely and efficiently treated over 600 patients with documenting each procedure. Methods:The purpose of our study is primarily to monitor the immune response in order to validate the safety of intravenous infusion of human umbilical cord blood derived MSCs (UC-MSCs), and secondly, to evaluate effects on biomarkers associated with chronic inflammation. Twenty patients were treated for conditions associated with chronic inflammation and for the purpose of anti-aging. They have been given one intravenous infusion of UC-MSCs. Results:Our study of blood test markers of 20 patients with chronic inflammation before and within three months after MSCs treatment demonstrates that there are no significant changes and MSCs treatment was safe for the patients. Analysis of different indicators of chronic inflammation and aging included in initial, 24-hours, two weeks and three months protocols showed that stem cell treatment was safe for the patients; there were no adverse reactions. Moreover, data from follow-up protocols demonstrate significant improvement in energy level, hair, nail growth and skin conditions. Conclusion:Intravenously administered UC-MSCs were safe and effective in the improvement of symptoms related to chronic inflammation. Further close monitoring and inclusion of more patients are necessary to fully characterize the advantages of UC-MSCs application in treatment of symptoms related to chronic inflammation.

Case report: Dendritic cell-cytokine induced killer cell therapy in subjects with chronic lymphocytic leukemia and peritoneal cancer

“…The subject received one intravenous infusion of umbilical cord-derived mesenchymal stem cells at a dose of 1.3 × 10 9 cells per 5 mL. Collection, isolation of MSCs from human umbilical cord blood, and quality control testing were performed according to methods described by Mehling et al ( 10 ). Following this, leukocyte numbers continued to rise until June 2018, when the patient underwent a further 6 sessions of chemotherapy.…”